Your Life your connection to The Boston Globe
White Coat Notes: News from the Boston-area medical community
Send your comments and tips to

Elizabeth Cooney is a health reporter for the Worcester Telegram & Gazette.
Boston Globe Health and Science staff:
Scott Allen
Alice Dembner
Carey Goldberg
Liz Kowalczyk
Stephen Smith
Colin Nickerson
Beth Daley
Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor.
 Short White Coat blogger Ishani Ganguli
 Short White Coat blogger Jennifer Srygley
Week of: November 11
Week of: November 4
Week of: October 28
Week of: October 21
Week of: October 14
Week of: October 7

« Nantucket's only surgeon sees it all | Main | Wong's Texas state of mind »

Monday, August 13, 2007

Today's Globe: autism triggers, plastic warning, diabetes and bones, bridge inspections, palliative care mission, cystic fibrosis drug deal

Researchers now believe that autism can be caused by genes in combination with environmental triggers. The question is, what are those triggers?

A federal panel of scientists concluded last week that an estrogen-like compound in plastic could be posing some risk to the brain development of babies and children.

As medicine struggles to halt the nation's diabetes epidemic, scientists have found a potential new weapon in the most unlikely place -- the skeleton.

bridge inspection100.bmpIt's a question that's been on a lot of commuters' minds over the last two weeks as they drive over area bridges (left, an inspection last week in Fitchburg): Why didn't engineers know that the Interstate 35 west bridge in Minneapolis was so close to disaster?

dr. bob buxbaum150.bmpMortality can only, at best, be delayed -- whether from cancer or anything else. So Dr. Bob Buxbaum (right) has devoted himself to palliative care, meaning he helps make a patient's life better once that life is coming to an end.

james bond100.bmpAlso in Health/Science, a stomach drug might have brain impact, do body-fat scales work and what's the difference between shaken and stirred?

In Business & Innovation, the Cambridge biotechnology firm FoldRx Pharmaceuticals Inc. will receive $22 million from the Cystic Fibrosis Foundation to develop and commercialize drugs aimed at treating the fatal genetic disease, a disorder of the lungs and digestive system that afflicts 70,000 people worldwide.

Posted by Elizabeth Cooney at 06:56 AM
Sponsored Links